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Koretz and colleagues argue that hepatitis C virus (HCV)
screening should be delayed.1 We disagree. HCV transmission
was common in the 1960s-80s, and because mortality occurs
30-40 years after infection deaths will rise exponentially over
the next decade.2 Delaying effective intervention will have a
massive impact. The authors argue that because a community
study showed an increase in liver and non-liver mortality most
infected people will not die from HCV. Infection can cause or
exacerbate renal disease, diabetes, and dyslipidaemia and
treatment reduces all cause mortality,3 indicating that both liver
and non-liver related deaths are caused by HCV and reversed
by treatment. Disease outcome is improved by lifestyle changes,
but this requires diagnosis. Identification also allows action to
reduce transmission, and because chronic infection is associated
with treatment reversible neurocognitive dysfunction, the
detection of infection has additional benefits.4
The benefits of viral elimination can be shown by comparing
mortality in treated patients who respond to treatment with those
who don’t. The authors argue that these benefits are due to
“differences in people who respond”—people who respond
don’t develop liver disease. If this were true, patients with
cirrhosis wouldn’t respond, but many are successfully treated,
with disease regressing.5 The authors compare different studies
with different underlying cancer rates and imply that cancer
incidence is the same in successfully and unsuccessfully treated
patients. This is misleading—comparisons within the same
cohorts show reduced liver cancer rates in treated patients. It is
not valid to take the highest cancer rate from a treated population
and compare it with a selected untreated population with a
strikingly low rate of cancer and conclude that treatment has no
effect.
Current standard of care for HCV no longer involves interferon
but uses oral drugs that eliminate virus in more than 90% of
cases.6 Telaprevir (with many side effects) has been replaced
by drugs that are virtually free from side effects—most side
effects in the pivotal trials of oral drugs were not drug related.
Independent European and US experts have reviewed the data
on HCV treatment and screening and conclude that increased
testing and screening is the right response. The development of
new highly effective drugs gives us an opportunity to eliminate
the harm caused by this virus. To delay a process with clear
benefit in order to satisfy demands for more data would expose
thousands of undiagnosed treatable patients to the risks of cancer
and cirrhosis. This must not be regarded as acceptable.
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